アロプリノールは,実験的な心筋梗塞後の左心室の改造と機能不全を弱める:古い薬の新しい作用?
Niels Engberding1, Stephan Spiekermann, Arnd Schaefer
1Abteilung Kardiologie und Angiologie, Medizinische Hochschule Hannover, Hannover, Germany.
Circulation
|October 7, 2004
まとめ
アロプリノール (xanthine oxidase inhibitor) は,反応性酸素種 (ROS) を減少させ,左心室 (LV) の改造と,マウスにおける心筋梗塞 (MI) の後の機能不全を防ぐ.
科学分野:
- 心臓病学 心臓病学
- バイオケミストリー バイオケミストリー
- 薬理学 薬理学とは
背景:
- 活性酸素種 (ROS) の増加は,心筋梗塞 (MI) の後の左心室 (LV) の改造と機能不全に貢献します.
- ザンチン酸化酵素 (XO) は,ROSの重要な源であり,心不全では発現が高くなりますが,LVの改造におけるその役割は不明です.
研究 の 目的:
- 強力なXO阻害剤であるアルロピュリノールによる長期治療が,心筋のROS産生と,心筋梗塞後のLVリモデリング/機能不全に及ぼす影響を調査する.
主な方法:
- 前頭筋梗塞のマウス (n=105) はランダムに4週間にわたってベクチャールまたはアロピュリノール (20mg/kg/日) を投与されました.
- 評価された心臓発作のサイズ,XO発現/活性,ROS産生,LV腔の寸法,LV機能,高縮,および線維症.
主要な成果:
- アロプーリノールは,車両治療と比較して,心筋のROS生成を著しく減少させた.
- アロプーリノール治療は,LVの膨張と機能不全を弱め,高縮とMI後の線維症を軽減しました.
- XO発現と活動は,心筋梗塞後の遠心筋で上昇した.
結論:
- アロプリノールは,実験的なMI後にLVリモデリングと機能不全を弱める新しい有益な効果を示しています.
- アロプーリノールは,不良なLVリモジレーションとMI後の機能不全を予防する潜在的な治療戦略を表しています.
さらに関連する動画
14:35Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs
Published on: April 17, 2021
05:41Left Anterior Descending Coronary Artery Ligation for Ischemia-Reperfusion Research: Model Improvement via Technical Modifications and Quality Control
Published on: December 16, 2022
関連する概念動画
01:22Heart Failure Drugs: Diuretics
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:22Heart Failure Drugs: β-Blockers
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
01:30Heart Failure V: Medical Management
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
01:29Cardiomyopathy V: Interprofessional Care
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...